Patents by Inventor Idenix Pharmaceuticals, Inc.

Idenix Pharmaceuticals, Inc. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MACROCYCLIC SERINE PROTEASE INHIBITORS
    Publication number: 20130224147
    Abstract: Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.
    Type: Application
    Filed: January 10, 2013
    Publication date: August 29, 2013
    Applicant: Idenix Pharmaceuticals, Inc.
    Inventor: Idenix Pharmaceuticals, Inc.
  • Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
    Publication number: 20130217644
    Abstract: Provided herein are pharmaceutical compositions, and in particular, oral pharmaceutical compositions, and methods of using these pharmaceutical compositions in the treatment of viral infections, including hepatitis C virus infections in hosts in need thereof. In certain embodiments, pharmaceutical compositions of 2?-C-methyl-guanosine, 5?-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl N-(phenylmethyl)phosphoramidate] are provided which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human.
    Type: Application
    Filed: February 8, 2013
    Publication date: August 22, 2013
    Applicant: IDENIX PHARMACEUTICALS, INC.
    Inventor: IDENIX PHARMACEUTICALS, INC.
  • METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS
    Publication number: 20130149283
    Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
    Type: Application
    Filed: December 28, 2012
    Publication date: June 13, 2013
    Applicants: UNIVERSITA DEGLI STUDI DI CAGLIARI, IDENIX PHARMACEUTICALS, INC.
    Inventors: IDENIX PHARMACEUTICALS, INC., UNIVERSITA DEGLI STUDI DI CAGLIARI
  • PHOSPHINATE RUTHENIUM COMPLEXES
    Publication number: 20130150572
    Abstract: Provided herein are ruthenium complexes of Formula I, and processes of preparation thereof. Also provided are methods of their use as a metathesis catalyst.
    Type: Application
    Filed: February 12, 2013
    Publication date: June 13, 2013
    Applicant: IDENIX PHARMACEUTICALS, INC.
    Inventor: Idenix Pharmaceuticals, Inc.
  • SUBSTITUTED 3',5'-CYCLIC PHOSPHATES OF PURINE NUCLEOTIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS
    Publication number: 20130095064
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections.
    Type: Application
    Filed: October 12, 2012
    Publication date: April 18, 2013
    Applicant: Idenix Pharmaceuticals, Inc.
    Inventor: Idenix Pharmaceuticals, Inc.
  • 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS
    Publication number: 20130071352
    Abstract: Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.
    Type: Application
    Filed: November 13, 2012
    Publication date: March 21, 2013
    Applicant: IDENIX PHARMACEUTICALS, INC.
    Inventor: Idenix Pharmaceuticals, Inc.
  • METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS
    Publication number: 20130017171
    Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
    Type: Application
    Filed: September 20, 2012
    Publication date: January 17, 2013
    Applicants: UNIVERSITA DEGLI STUDI DI CAGLIARI, IDENIX PHARMACEUTICALS, INC.
    Inventors: Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari